NCT 01858558 evaluated the efficacy of adding MILs to maintenance therapy in high-risk myeloma patients post-ASCT and NCT 01045460 randomized myeloma patients post-ASCT to either MILs alone vs MILs + the allogeneic granulocyte macrophage colony-stimulating factor-based myeloma cellular vaccine. Here, CSF2 is linked to plasma cell myeloma.